While it was correct when it noted noted that Dr. M took AVXL from a literal penny stock 10 years ago, by the time the p2b/p3 trial was run, Dr. M had done his magic on the finances and the company was on the 4 years of cash runway plan. So as a reason for slow rollout of p2b/p3 that doesnt really make literal sense, although perhaps he meant that he didn't want to stress cash flow ( and dilution) so they kept it in easily digested segments. either way, he at least acknowledged concerns that the rollout was slow.
generally acknowledged that Dr. M has been genius at low cost financing and minimizing dilution.